These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8508412)

  • 21. Prognostic significance of molecular staging by PCR-amplification of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma (DLBCL).
    Mitterbauer-Hohendanner G; Mannhalter C; Winkler K; Mitterbauer M; Skrabs C; Chott A; Simonitsch-Klupp I; Gleiss A; Lechner K; Jaeger U
    Leukemia; 2004 Jun; 18(6):1102-7. PubMed ID: 15085149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of oncogene rearrangements in human non-Hodgkin's lymphomas.
    Kondo E; Yoshino T; Akagi T; Hayashi K; Takahashi K
    Acta Med Okayama; 1992 Dec; 46(6):407-15. PubMed ID: 1485535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MYC and aggressive B-cell lymphomas.
    Slack GW; Gascoyne RD
    Adv Anat Pathol; 2011 May; 18(3):219-28. PubMed ID: 21490439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.
    Wilson KS; Sehn LH; Berry B; Chhanabhai M; Fitzgerald CA; Gill KK; Klasa R; Skinnider B; Sutherland J; Connors JM; Gascoyne RD
    Leuk Lymphoma; 2007 Jun; 48(6):1102-9. PubMed ID: 17577773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinicopathologic significance of bcl-6 gene rearrangement and expression in three molecular subgroups of diffuse large B-cell lymphoma].
    Xu FP; Liu YH; Luo XL; Zhuang HG; Li L; Luo DL; Xu J; Zhang F; Zhang MH; Du X; Li WY
    Zhonghua Bing Li Xue Za Zhi; 2008 Jun; 37(6):371-6. PubMed ID: 19031715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
    [No Abstract]   [Full Text] [Related]  

  • 27. Frequency of bcl-2 gene rearrangement in B-cell Non-Hodgkin's lymphoma.
    Arif A; Jamal S; Mushtaq S; Ahmed S; Mubarik A
    Asian Pac J Cancer Prev; 2009; 10(2):237-40. PubMed ID: 19537891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
    Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma.
    Vitolo U; Botto B; Capello D; Vivenza D; Zagonel V; Gloghini A; Novero D; Parvis G; Calvi R; Ariatti C; Milan I; Bertini M; Boccomini C; Freilone R; Pregno P; Orsucci L; Palestro G; Saglio G; Carbone A; Gallo E; Gaidano G
    Leukemia; 2002 Feb; 16(2):268-75. PubMed ID: 11840294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma.
    Iqbal J; Sanger WG; Horsman DE; Rosenwald A; Pickering DL; Dave B; Dave S; Xiao L; Cao K; Zhu Q; Sherman S; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Ott G; Müller-Hermelink HK; Delabie J; Braziel RM; Jaffe ES; Campo E; Lynch JC; Connors JM; Vose JM; Armitage JO; Grogan TM; Staudt LM; Chan WC
    Am J Pathol; 2004 Jul; 165(1):159-66. PubMed ID: 15215171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New chromosome abnormalities and lack of BCL-6 gene rearrangements in Argentinean diffuse large B-cell lymphomas.
    Cerretini R; Noriega MF; Narbaitz M; Slavutsky I
    Eur J Haematol; 2006 Apr; 76(4):284-93. PubMed ID: 16519699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Assessment of BIOMED-2 assays for detection of clonal Ig gene rearrangements in mature B-cell lymphomas].
    Zhang J; Wu YH; Kong HY; Zhou XG; Jin HS; Wu XM; Zhang DD; Gong LP
    Zhonghua Bing Li Xue Za Zhi; 2009 Nov; 38(11):739-44. PubMed ID: 20079012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma.
    Llanos M; Alvarez-Argüelles H; Alemán R; Oramas J; Diaz-Flores L; Batista N
    Med Oncol; 2001; 18(1):15-22. PubMed ID: 11778965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
    Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
    Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma.
    Offit K; Lo Coco F; Louie DC; Parsa NZ; Leung D; Portlock C; Ye BH; Lista F; Filippa DA; Rosenbaum A
    N Engl J Med; 1994 Jul; 331(2):74-80. PubMed ID: 8208268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases.
    Tang SC; Visser L; Hepperle B; Hanson J; Poppema S
    J Clin Oncol; 1994 Jan; 12(1):149-54. PubMed ID: 8270971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Long-term remission after CHOP therapy in a case of multifocal extranodal diffuse large B-cell lymphoma with t(1 ; 14) (p22 ; q32) and rearrangement of bcl-10].
    Sakai R; Kanamori H; Ishigatsubo Y
    Rinsho Ketsueki; 2005 Oct; 46(10):1105-8. PubMed ID: 16440771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Large B-cell lymphoma with Hodgkin's features.
    García JF; Mollejo M; Fraga M; Forteza J; Muniesa JA; Pérez-Guillermo M; Pérez-Seoane C; Rivera T; Ortega P; Piris MA
    Histopathology; 2005 Jul; 47(1):101-10. PubMed ID: 15982329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
    Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
    Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma.
    Wang XJ; Seegmiller AC; Reddy NM; Li S
    Eur J Haematol; 2016 Jul; 97(1):39-47. PubMed ID: 26340843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.